JP2025114807A5 - - Google Patents

Info

Publication number
JP2025114807A5
JP2025114807A5 JP2025080907A JP2025080907A JP2025114807A5 JP 2025114807 A5 JP2025114807 A5 JP 2025114807A5 JP 2025080907 A JP2025080907 A JP 2025080907A JP 2025080907 A JP2025080907 A JP 2025080907A JP 2025114807 A5 JP2025114807 A5 JP 2025114807A5
Authority
JP
Japan
Prior art keywords
antigen
binding molecule
domain
molecule
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025080907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025114807A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/045309 external-priority patent/WO2021026409A1/en
Application filed filed Critical
Publication of JP2025114807A publication Critical patent/JP2025114807A/ja
Publication of JP2025114807A5 publication Critical patent/JP2025114807A5/ja
Pending legal-status Critical Current

Links

JP2025080907A 2019-08-08 2025-05-14 新規抗原結合分子フォーマット Pending JP2025114807A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962884496P 2019-08-08 2019-08-08
US62/884,496 2019-08-08
US202063050483P 2020-07-10 2020-07-10
US63/050,483 2020-07-10
PCT/US2020/045309 WO2021026409A1 (en) 2019-08-08 2020-08-07 Novel antigen binding molecule formats
JP2022507737A JP7682853B2 (ja) 2019-08-08 2020-08-07 新規抗原結合分子フォーマット

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022507737A Division JP7682853B2 (ja) 2019-08-08 2020-08-07 新規抗原結合分子フォーマット

Publications (2)

Publication Number Publication Date
JP2025114807A JP2025114807A (ja) 2025-08-05
JP2025114807A5 true JP2025114807A5 (cg-RX-API-DMAC7.html) 2025-09-04

Family

ID=72179250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507737A Active JP7682853B2 (ja) 2019-08-08 2020-08-07 新規抗原結合分子フォーマット
JP2025080907A Pending JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022507737A Active JP7682853B2 (ja) 2019-08-08 2020-08-07 新規抗原結合分子フォーマット

Country Status (12)

Country Link
US (8) US12215148B2 (cg-RX-API-DMAC7.html)
EP (1) EP4010371A1 (cg-RX-API-DMAC7.html)
JP (2) JP7682853B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220058546A (cg-RX-API-DMAC7.html)
CN (3) CN114585651A (cg-RX-API-DMAC7.html)
AU (1) AU2020327000A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022002067A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150168A1 (cg-RX-API-DMAC7.html)
IL (1) IL290371A (cg-RX-API-DMAC7.html)
MX (1) MX2022001682A (cg-RX-API-DMAC7.html)
TW (1) TW202120556A (cg-RX-API-DMAC7.html)
WO (1) WO2021026409A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074541A (zh) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
CN114585651A (zh) * 2019-08-08 2022-06-03 再生元制药公司 新型抗原结合分子形式
EP4090369A4 (en) * 2020-01-15 2024-06-26 The Board of Trustees of the Leland Stanford Junior University PERICYTE-SPARKING THERAPY
US20230242605A1 (en) * 2020-06-19 2023-08-03 Sookmyung Women's University Industry-Academic Cooperation Foundation Mutation complex including gain-of-function mutant of bmpr2 gene, induced pluripotent stem cells and mesenchymal stem cells derived from mutant, and use thereof
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
SG176219A1 (en) * 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EP2511718B1 (en) 2009-12-07 2017-07-05 Ntt Docomo, Inc. Propagation path estimation method, program, and device
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
SG185416A1 (en) * 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
EP2970485A1 (en) 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US10717783B2 (en) 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
CN207626880U (zh) 2017-05-19 2018-07-20 厦门汇成峰户外用品有限公司 一种导演椅
IL274071B2 (en) 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
BR112020008031A2 (pt) * 2017-11-01 2020-10-27 F. Hoffmann-La Roche Ag anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
WO2020047067A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN114585651A (zh) * 2019-08-08 2022-06-03 再生元制药公司 新型抗原结合分子形式

Similar Documents

Publication Publication Date Title
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
Brinkmann et al. The making of bispecific antibodies
JP2022543669A5 (cg-RX-API-DMAC7.html)
KR101522954B1 (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
JP6104121B2 (ja) 操作されたヘテロ二量体タンパク質ドメイン
JP2025000628A5 (cg-RX-API-DMAC7.html)
JP2021042257A5 (cg-RX-API-DMAC7.html)
CN115698052A (zh) 白介素2突变体及其用途
CN118063619A (zh) 工程化的异源二聚体蛋白质
JP2009539412A5 (cg-RX-API-DMAC7.html)
JP2024511465A5 (cg-RX-API-DMAC7.html)
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
CN116284396B (zh) NKp46抗体及其用途
US20260085113A1 (en) All-in-one agonistic antibodies
CN114585651A (zh) 新型抗原结合分子形式
JP2024531346A5 (cg-RX-API-DMAC7.html)
RU2022105671A (ru) Новые форматы антигенсвязывающих молекул
WO2025092987A1 (zh) 基于Fc区的异二聚体分子及其用途
JP2025528101A5 (cg-RX-API-DMAC7.html)
HK40079873A (en) Hetero-dimeric multi-specific antibody format
EA041608B1 (ru) Гетеродимерный полиспецифичный формат антител